Actively Recruiting
A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
Led by Centessa Pharmaceuticals (UK) Limited · Updated on 2025-12-24
208
Participants Needed
3
Research Sites
50 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.
CONDITIONS
Official Title
A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy males or females as determined by screening assessments
- Participants aged 18 to 55 years for Parts A, B, C, and E
- Participants aged 60 to 80 years for Part D
You will not qualify if you...
- Significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological, or psychiatric disease
- History of seizure disorder or any condition increasing seizure risk
- Clinically significant sleep disorder, including insomnia or sleep apnea
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Site #1
Lincoln, Nebraska, United States, 68502
Actively Recruiting
2
Site #2
Eatontown, New Jersey, United States, 07724
Actively Recruiting
3
Site #3
New York, New York, United States, 10019
Actively Recruiting
Research Team
O
ORX142 Centessa Program Lead
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here